Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Patients with Gastrointestinal Side Effects: Case Studies

Abstract

Background

The potential benefit of the current mycophenolic acid, mycophenolate mofetil, has not yet been fully achieved in clinical transplantation because of its gastrointestinal side effects. Dose splitting, dose reduction, and drug discontinuation are strategies that are used to manage gastrointestinal symptoms. However, recently reported registry data suggest these alterations result in inadequate graft protection, leading to increased late acute rejection rates and decreased long-term graft survival.

Objective

To investigate the potential use of the new enteric-coated formulation of mycophenolic acid therapy, mycophenolate sodium, and its suggested improved side effects profile.

Participants

Five patients who previously had or were currently experiencing gastrointestinal side effects while taking mycophenolate mofetil were selected at random. These patients were initially switched to an equimolar dose of enteric-coated mycophenolate sodium. An increase in mycophenolate sodium doses was attempted according to symptoms. Changes in kidney function and gastrointestinal symptom scores were recorded before and after conversion.

Results

No episodes of acute rejection were observed in any patients during or after conversion. All patients experienced an overall improvement in gastrointestinal symptom scores following conversion, and an increase in mycophenolate sodium dose was achieved in 1 patient.

Get full access to this article

View all access options for this article.

References

Helderman

. Prophylaxis and treatment of gastrointestinal complications following transplantation. Clin Transplant. 2001;15(suppl 4):29–35.

Behrend

. Adverse gastrointestinal effects of mycophenolate mofetil, aetiology, incidences and management. Drug Safety. 2001;24:645–663.

Pelletier

Akin

Henry

Bumgardner

Elkhammas

Ferguson

. The impact of Mycophenolate Mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant. 2003;17:200–205.

Hardinger

Brennan

Lowell

Schnitzler

. Long-term outcome of gastrointestinal complications in renal transplant patients treated with Mycophenolate Mofetil. Transpl Int. 2004;17:609–616

Salvadori

Holzer

de Mattos

. Enteric-coated Mycophenolate Sodium is therapeutically equivalent to MMF in de novo renal transplant patients. Am J Transplant. 2004;4:231–236.

Granger

. Enteric-coated Mycophenolate sodium: Results of two pivotal global multicentre trials. Transplant Proc. 2001;33:3241–3244.

Budde

Curtis

Knoll

Chan

Neumayer

Seifu

. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: Results of a 1-year study. Am J Transplant. 2004;4:237–243.

Dimenas

Carlsson

Glise

Israelsson

Wiklund

. Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand J Gastroenterol. 1996;221(suppl):8–13.